Clinical trials: Fibrillation, Atrial
Atrial Fibrillation
Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)
This study is prospective Cohort study which was performed in multicenter (General Hospital) in Korea. Inclusion criteria is all patients with atrial fibrillation who visit hospital.
- Trial name
- NCT02786095
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Yonsei University
Atrial Fibrillation
Candesartan in the Prevention of Relapsing Atrial Fibrillation
The purpose of this study is to test the hypothesis that treatment with the angiotensin II type 1 receptor antagonist candesartan may reduce the recurrence rate of atrial fibrillation after electrical cardioversion.
- Trial name
- NCT00130975
- Testing
- Candesartan
- Where
- 2 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Asker & Baerum Hospital
Atrial Fibrillation
Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation
The purpose of this study is to assess if pre-ablation levels of inflammatory biomarkers serve as independent predictors of procedure outcome To evaluate the inflammatory activation following catheter ablation by measuring…
- Trial name
- IMPACTII (NCT02208102)
- Testing
- Radio-frequency catheter ablation
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Texas Cardiac Arrhythmia Research Foundation
Cardiovascular Diseases, Coronary Disease
Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups
Cardiovascular disease (CVD) is one of the leading causes of death in the United States. Currently, there is little information about the lifetime risk of CVD among non-white ethnic groups.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Failure, Congestive, Atrial Fibrillation
- Trial name
- NCT00377702
- Where
- United States
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation
STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial
Patient Population: Patients with AF that is symptomatic and refractory to at least one antiarrhythmic medication. Patients must have AF that is paroxysmal (>4 episodes within 6 months, two episodes >6 hours within 1 year) or…
- Trial name
- NCT00367757
- Testing
- Ablate AF triggers via PVI, Substrate via CFAEs, Combined approach for AF ablation
- Where
- 8 sites in Canada, Italy and 2 more
- Volunteers
- 107 people
- Sponsor
- Abbott Medical Devices
Acute Ischemic Stroke, Atrial Fibrillation
Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF
The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- ASAP (NCT06057467)
- Testing
- Anticoagulation Agents
- Where
- 2 sites in China
- Volunteers
- 2,351 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atrial Fibrillation
Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration > 72…
- Trial name
- NCT00526136
- Testing
- Vernakalant (oral)
- Where
- 152 sites in Australia, Belgium and 22 more
- Volunteers
- 735 people
- Sponsor
- Advanz Pharma
Atrial Fibrillation
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
To demonstrate safety and effectiveness of nMARQ Catheter System [nMARQ] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).
- Trial name
- NCT01824394
- Testing
- nMARQ Navigation Catheters, NaviStar ThermoCool Catheters
- Volunteers
- 481 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation
The Genetic Basis for Atrial Fibrillation
Atrial fibrillation (AF) is reaching epidemic proportions in the aging U.S. and European populations, but the mechanisms of increased susceptibility to atrial fibrillation are still unknown.
- Trial name
- NCT03491202
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Jesse Brown VA Medical Center
Atrial Fibrillation, Atrial Fibrillation Paroxysmal
Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation
Rationale: Although there are several individual factors which are known to influence the chances of successful atrial fibrillation (AF) ablation, it remains a challenge to identify patients at risk for ablation failure with…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent
- Trial name
- ISOLATION (NCT04342312)
- Testing
- Pulmonary vein isolation
- Where
- 2 sites in Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University
Atrial Fibrillation, Persistent Atrial Fibrillation
PLAI-AF Trial: Hybrid Endo-epicardial Partial Left Atrial Isolation vs. Endocardial Ablation in Patients With Persistent Atrial Fibrillation
In patients with symptomatic atrial fibrillation (AF), current clinical guidelines recommend ablation for rhythm control. While percutaneous ablation has good results in patients with paroxysmal AF, it is not clear which is the…
- Conditions
- Atrial Fibrillation, Persistent Atrial Fibrillation, Arrythmia
- Trial name
- PLAI-AF (NCT05723536)
- Testing
- Partial Left Atrial Isolation, Catheter Ablation
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
Obstructive Sleep Apnea, Sleep Disorder (Disorder)
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%.
- Conditions
- Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
- Trial name
- STOP-AFib (NCT07444372)
- Testing
- Continuous Positive Airway Pressure (CPAP), Usual Care
- Where
- 30 sites in China
- Volunteers
- 658 people
- Sponsor
- Beijing Anzhen Hospital
Cardiovascular Diseases, Atrial Fibrillation
A Digital Flu Intervention for People With Cardiovascular Conditions
A 6-month prospective, digital randomized controlled trial targeting approximately 49,000 individuals to evaluate the effectiveness of an influenza vaccination intervention during influenza season for people with cardiovascular…
- Conditions
- Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest
- Trial name
- CardioFlu (NCT04584645)
- Testing
- Targeted digital intervention
- Where
- United States
- Volunteers
- 49,138 people
- Sponsor
- Evidation Health
Cardioembolic Stroke, Multidisciplinary Communication
A Real-world Registry Study of Multidisciplinary Collaborative Diagnosis and Treatment Model for Cardioembolic Stroke
Study Title: A real-world registry of multidisciplinary collaborative diagnosis and treatment models for cardioembolic stroke Research Objectives: ① Main objective: To establish a multidisciplinary assisted diagnosis and…
- Trial name
- CSMDT (NCT05498909)
- Testing
- Multidisciplinary joint diagnosis and treatment mode
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Xiao Huang
Atrial Fibrillation Recurrent, Hypertension
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
Study name: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation. Medicine: sacubitril/valsartan (100mg) and valsartan (80mg).
- Trial name
- NCT05528419
- Testing
- Sacubitril-valsartan, Valsartan
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Atrial Fibrillation (AF), Stroke
Elite AF IDE Trial (Elite AF)
The primary objective of this study is to establish the safety and effectiveness of the WATCHMAN Elite Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation who are eligible for…
- Trial name
- NCT07287436
- Testing
- WATCHMAN Elite LAAC Device
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
This is a prospective, adaptive, multi-center, randomized safety and effectiveness pivotal study comparing the FARAPULSE Pulsed Field Ablation System with standard of care ablation with force-sensing RF catheters and cryoballoon…
- Trial name
- ADVENT (NCT04612244)
- Testing
- FARAPULSE Pulsed Field Ablation System, RadioFrequency and Cryoballoon Ablation
- Where
- 34 sites in United States
- Volunteers
- 706 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Stroke
Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden
The purpose of this study is to determine whether screening for atrial fibrillation by intermittent ECG recording and initiation of anticoagulation treatment among high risk individuals is cost-effective and can lower the…
- Trial name
- NCT01593553
- Testing
- ECG screening for atrial fibrillation using intermittent ECG recorder
- Where
- Sweden
- Volunteers
- 7,173 people, healthy volunteers welcome
- Sponsor
- Karolinska University Hospital
Atrial Fibrillation
hsTnT in Patients Admitted to the ED With Atrial Fibrillation in the Era of NOACs - Heidelberg Registry of Atrial Fibrillation
The purpose of the Heidelberg Registry of Atrial Fibrillation (HERA-FIB) is to collect data on the prevalence and clinical significance of elevated cardiac troponin in a large registry of unselected patients with atrial…
- Trial name
- HERA-FIB (NCT03344237)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Heidelberg
Atrial Fibrillation
GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence
Study purpose The purpose of the study is to show that the addition of valsartan on top of established therapies can reduce the recurrence of atrial fibrillation in patients with a history of recent atrial fibrillation associated…
- Trial name
- NCT00376272
- Testing
- Valsartan
- Where
- 114 sites in Italy, Switzerland
- Volunteers
- 1,442 people
- Sponsor
- Gruppo di Ricerca GISSI